ReviewCNS & neurological disorders drug targets2026
Organosulfur Compounds: Potential Therapeutics for Parkinson's Disease.
Review in CNS & neurological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several organosulfur compounds exhibit anti-Parkinson's disease (PD) activities. PD is a progressive and chronic neurodegenerative condition that causes motor and non-motor symptoms that severely reduce quality of life. A selective loss of dopaminergic neurons in the substantia nigra, in addition to several neuropathological mechanisms, has been implicated in PD. The present therapeutic techniques are mostly focused on providing symptomatic relief and frequently have significant side effects, which underscores the pressing need for innovative medicines that address the underlying causes of disease. Several organosulfur compounds, both synthesized and naturally occurring analogues, have gained attention as potential anti-PD molecules because of their wide range of biological activities, which include anti-inflammatory, neuroprotective, and antioxidant capabilities. Several organosulfur compounds have been shown to have potential neuroprotective benefits in preclinical research on PD. Their ability to attenuate neuroinflammation, oxidative stress, apoptosis, and mitochondrial dysfunction, which are central to PD pathogenesis via modulation of cellular pathways and endogenous antioxidant defenses, provides multifaceted approaches to neuroprotection in PD. Thus, the current review provides the state of the art on the potential therapeutic effects of organosulfur compounds in PD. The natural and synthetic sources of anti-PD organosulfur compounds, including their physical properties, chemical properties, structure-activity relationship (SAR), and therapeutic effects in PD, were discussed. The challenges and future directions of organosulfur compounds as potential anti-PD drugs and their clinical trial prospects were also highlighted. This is aimed at paving the way for the development of more effective and sustainable treatment strategies for PD.
Indexed as
Identifiers
40739688What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.